Company
Company Information
History
Access
R&D
Technology
Technology Platform
NJA-730
Napa9-SPG
Business Development
Drug Discovery and Development Collaboration
Licensing Opportunity
News
Press release
Academic
Contact
HOME
»
news
news Archives
2018-11-15
news
NapaJen Pharma, Co., Ltd. initiates Phase 1 study of NJA-730, an RNAi therapeutic with a Unique Delivery Technology
